Acyl-glucuronide as a possible cause of trovafloxacin-induced liver toxicity: Induction of chemokine (C-X-C motif) ligand 2 by trovafloxacin acyl-glucuronide

Biological and Pharmaceutical Bulletin

Volumn 39, Issue 10, 2016, Pages 1604-1610

  Mitsugi, Ryo ^a   Sumida, Kyohei ^a   Fujie, Yoshiko ^a   Tukey, Robert H ^b   Itoh, Tomoo ^a   Fujiwara, Ryoichi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acyl glucuronide; Chrysin; Drug induced liver injury; HepG2 cell; Trovafloxacin

Indexed keywords

ACYL GLUCURONIDE; ALANINE AMINOTRANSFERASE; CHRYSIN; CXCL2 CHEMOKINE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; TROVAFLOXACIN; UNCLASSIFIED DRUG; FLAVONOID; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; UGT1A1 ENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LIVER TOXICITY; MOUSE; NONHUMAN; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; METABOLISM; TOXIC HEPATITIS; TRANSGENIC MOUSE;

ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMOKINE CXCL2; FLAVONOIDS; FLUOROQUINOLONES; GENE EXPRESSION REGULATION; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEP G2 CELLS; HUMANS; MICE, TRANSGENIC; NAPHTHYRIDINES; RNA, MESSENGER;

EID: 84989313360     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b16-00195     Document Type: Article

References (41)

1. Dutton GJ. Acceptor substrates of UDP glucuronosyltransferase and their assay, in Glucuronidation of Drugs and Other Compounds (Dutton GJ ed). pp. 69-78, CRC Press, Boca Raton, FL (1980).
2. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro SI, Iyanagi T, Miners JO, Owens IS, Nebert DW. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics, 15, 677-685 (2005).
3. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, Owens IS. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem., 267, 3257-3261 (1992).
4. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 40, 581-616 (2000).
5. Fujiwara R, Maruo Y, Chen S, Tukey RH. Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia. Toxicol. Appl. Pharmacol., 289, 124-132 (2015).
6. Kaminsky LS, Zhang QY. The small intestine as a xenobiotic-metabolizing organ. Drug Metab. Dispos., 31, 1520-1525 (2003).
7. Gootz TD, McGuirk PR. New quinolones in development. Expert Opin. Investig. Drugs, 3, 93-114 (1994).
8. Dalvie DK, Khosla N, Vincent J. Excretion and metabolism of trovafloxacin in humans. Drug Metab. Dispos., 25, 423-427 (1997).
9. Pumford NR, Myers TG, Davila JC, Highet RJ, Pohl LR. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol., 6, 147-150 (1993).
10. Kutsuno Y, Itoh T, Tukey RH, Fujiwara R. Glucuronidation of drugs and druginduced toxicity in humanized UDP-glucuronosyltransferase 1 mice. Drug Metab. Dispos., 42, 1146-1152 (2014).
11. Miyashita T, Kimura K, Fukami T, Nakajima M, Yokoi T. Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs. Drug Metab. Dispos., 42, 1-8 (2014).
12. Koga T, Fujiwara R, Nakajima M, Yokoi T. Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. Drug Metab. Dispos., 39, 54-60 (2011).
13. Liguori MJ, Blomme EA, Waring JF. Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab. Dispos., 36, 223-233 (2008).
14. Liguori MJ, Anderson MG, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, Waring JF. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology, 41, 177-186 (2005).
15. Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther., 316, 1080-1087 (2006).
16. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother., 44, 2600-2603 (2000).
17. Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, Friedman HL. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J. Antimicrob. Chemother., 39 (Suppl. 2), 75-80 (1997).
18. Olsen KM, Rebuck JA, Weidenbach T, Fish DN. Pharmacokinetics of intravenous trovafloxacin in critically ill adults. Pharmacotherapy, 20, 400-404 (2000).
19. Fujiwara R, Sumida K, Kutsuno Y, Sakamoto M, Itoh T. UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin. Drug Metab. Pharmacokinet., 30, 82-88 (2015).
20. Kutsuno Y, Hirashima R, Sakamoto M, Ushikubo H, Michimae H, Itoh T, Tukey RH, Fujiwara R. Expression of UDP-glucuronosyltransferase 1 (UGT1) and glucuronidation activity toward endogenous substances in humanized UGT1 mouse brain. Drug Metab. Dispos., 43, 1071-1076 (2015).
21. Fujiwara R, Takenaka S, Hashimoto M, Narawa T, Itoh T. Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. Sci. Rep., 4, 5251 (2014).
22. Sumida K, Kawana M, Kouno E, Itoh T, Takano S, Narawa T, Tukey RH, Fujiwara R. Importance of UDP-glucuronosyltransferase1A1 expression in skin and its induction by UVB in neonatal hyperbilirubinemia. Mol. Pharmacol., 84, 679-686 (2013).
23. Nguyen N, Bonzo JA, Chen S, Chouinard S, Kelner MJ, Hardiman G, Bélanger A, Tukey RH. Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J. Biol. Chem., 283, 7901-7911 (2008).
24. Fujiwara R, Nguyen N, Chen S, Tukey RH. Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc. Natl. Acad. Sci. U.S.A., 107, 5024-5029 (2010).
25. Aoshima N, Fujie Y, Itoh T, Tukey RH, Fujiwara R. Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia. Sci. Rep., 4, 6343 (2014).
26. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos., 32, 140-148 (2004).
27. Ritter JK, Kessler FK, Thompson MT, Grove AD, Auyeung DJ, Fisher RA. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences. Hepatology, 30, 476-484 (1999).
28. Westerink WM, Schoonen WG. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro, 21, 1592-1602 (2007).
29. Miners JO, Mackenzie PI, Knights KM. The prediction of drugglucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab. Rev., 42, 196-208 (2010).
30. Yano A, Oda S, Fukami T, Nakajima M, Yokoi T. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol. Lett., 228, 13-24 (2014).
31. Toyoda Y, Miyashita T, Endo S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol. Lett., 204, 17-24 (2011).
32. Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R, Blanchard J, Edwards MJ, Lentsch AB. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice. Hepatology, 48, 1213-1223 (2008).
33. Xu J, Lee G, Wang H, Vierling JM, Maher JJ. Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am. J. Physiol. Gastrointest. Liver Physiol., 287, G734-G741 (2004).
34. Moles A, Murphy L, Wilson CL, Chakraborty JB, Fox C, Park EJ, Mann J, Oakley F, Howarth R, Brain J, Masson S, Karin M, Seki E, Mann DAA. A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse. J. Hepatol., 60, 782-791 (2014).
35. James LP, McCullough SS, Lamps LW, Hinson JA. Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. Toxicol. Sci., 75, 458-467 (2003).
36. Yokoi T. New prospectives and understanding in drug-induced liver injury considering drug metabolism and immune- and inflammation-related factors. Folia Pharmacologica Japonica, 144, 22-27 (2014).
37. Shaw PJ, Ganey PE, Roth RA. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J. Pharmacol. Exp. Ther., 330, 72-78 (2009).
38. Bonzo JA, Bélanger A, Tukey RH. The role of chrysin and the ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice. Hepatology, 45, 349-360 (2007).
39. Smith CM, Graham RA, Krol WL, Silver IS, Negishi M, Wang H, Lecluyse EL. Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 cells. J. Pharmacol. Exp. Ther., 315, 1256-1264 (2005).
40. Fujiwara R, Nakajima M, Oda S, Yamanaka H, Ikushiro S, Sakaki T, Yokoi T. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J. Pharm. Sci., 99, 442-454 (2010).
41. Fujiwara R, Itoh T. Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes. Drug Metab. Pharmacokinet., 29, 259-265 (2014).